Table 4.
Correlation coefficients between serum UA and other clinical factors in patients and controls
| Serum UA | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PD | MSA | PSP | Controls | |||||||||
| Total | Men | Women | Total | Men | Women | Total | Men | Women | Total | Men | Women | |
| Age | −0.039 | −0.049 | −0.040 | 0.150 | −0.19 | 0.43 | 0.14 | 0.15 | 0.096 | −0.44 | 0.027 | 0.12 |
| BMI | 0.19 | 0.30* | 0.024 | 0.49** | 0.17 | 0.75** | 0.57** | 0.66** | 0.56* | 0.27* | 0.23 | 0.19 |
| MMSE | −0.080 | 0.22 | −0.13 | −0.23 | −0.14 | −0.26 | 0.13 | 0.13 | 0.017 | – | – | – |
| Disease duration | 0.054 | 0.20 | −0.038 | −0.31* | −0.34 | −0.18 | −0.37* | −0.70** | −0.011 | – | – | – |
| HY stage | −0.085 | −0.24 | 0.11 | −0.39* | −0.24 | −0.44 | −0.44* | −0.59* | −0.23 | – | – | – |
| UPDRS III | −0.010 | −0.18 | 0.11 | −0.24 | −0.35 | −0.11 | −0.49** | −0.62* | −0.095 | 0.063 | – | – |
| UMSARS II | – | – | – | −0.32* | −0.34 | −0.28 | – | – | – | – | – | – |
| LED | −0.015 | 0.020 | 0.020 | −0.21 | −0.003 | −0.25 | −0.36 | −0.26 | −0.54* | – | – | – |
UA, uric acid; BMI, body mass index; HY, Hoehn and Yahr; PD, Parkinson's disease; MSA, multiple system atrophy; PSP, progressive supranuclear palsy; MMSE, Mini‐Mental State Examination; UPDRS, Unified PD Rating Scale; UMSARS, Unified MSA Rating Scale; LED, levodopa‐equivalent dose.
*p < .05, **p < .01, ***p < .001; Spearman's rank correlation.